Recerca

Tractament del càncer pediàtric

Buscador de publicacions

Publicacions

  • García-Gerique L, Garcia-López M, Garrido- García A, Gómez-González S, Torrebadell-Burriel M, Prada-Varela E, Pascual-Pastó G, Muñoz-Aznar O, Pérez-Jaume S, Lemos I, Salvador-Marcos N, Vilà-Ubach M, Doncel-Requena A, Suñol M, Carcaboso AM, Mora J and Lavarino C.

    MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment

    BMC Cancer . 22(1): 669-669. Nº de cites: 8

    [doi:10.1186/s12885-022-09725-8]

  • Cañete A, Peris-Bonet R, Capocaccia R, Pardo-Romaguera E, Segura V, Muñoz-López A, Fernández-Teijeiro A, Galceran-Padros J, Gatta G and Spanish Neuroblastoma Linkage Working Group (SpNbLinkWG).

    Neuroblastoma in Spain: Linking the national clinical database and epidemiological registries - A study by the Joint Action on Rare Cancers.

    CANCER EPIDEMIOL . 78: 102145-102145.

    [doi:10.1016/j.canep.2022.102145]

  • Gonçalves-Alves E, Garcia-López M, Rodriguez-Hernandez CJ, Gomez-Gonzalez S, Ecker RC, Suñol M, Muñoz-Aznar O, Carcaboso AM, Mora J, Lavarino C and Mateo-Lozano S.

    AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES . 23(8): 4323. Nº de cites: 3

    [doi:10.3390/ijms23084323]

  • Schaiquevich P, Francis JH, Cancela MB, Carcaboso AM, Chantada G and Abramson DH.

    Treatment of Retinoblastoma: What Is the Latest and What Is the Future

    Frontiers in oncology . 12: 822330-822330. Nº de cites: 30

    [doi:10.3389/fonc.2022.822330]

  • Matthay KK, Hylton J, Penumarthy N, Khattab M, Soh SY, Nguyen HTK, Alcasabas AP, Fawzy M, Saab R, Khan MS, Ghandour K, Chantada G, Parikh NS, Faulkner L, Lam CG and Howard SC.

    Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resource-limited countries.

    PEDIATRIC BLOOD & CANCER . 69(4): . Nº de cites: 4

    [doi:10.1002/pbc.29568]

  • Sniderman ER, Graetz DE, Agulnik A, Ranadive R, Vedaraju Y, Chen Y, Devidas M, Chantada G, Hessissen L, Dalvi R, Pritchard-Jones K, Rodriguez-Galindo C and Moreira DC.

    Impact of the COVID-19 pandemic on pediatric oncology providers globally: A mixed-methods study

    CANCER . 128(7): 1493-1502. Nº de cites: 16

    [doi:10.1002/cncr.34090]

  • Diaz Coronado RY, Mynarek M, Koelsche C, Mora Alferez P, Casavilca Zambrano S, Wachtel Aptowitzer A, Sahm F, von Deimling A, Schüller U, Spohn M, Sturm D, Pfister SM, Morales-La Madrid A, Sernaque Quintana R, Sarria Bardales G, Negreiros Chinchihuara T, Ojeda Medina L, Garcia-Corrochano Medina P, Campos Sanchez DA, Ponce Farfan J, Rutkowski S and Garcia Leon JL.

    Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients.

    CANCER . 128(4): 697-707. Nº de cites: 17

    [doi:10.1002/cncr.33977]

  • Khadka P, Reitman ZJ, Lu S, Buchan G, Gionet G, Dubois F, Carvalho DM, Shih J, Zhang S, Greenwald NF, Zack T, Shapira O, Pelton K, Hartley R, Bear H, Georgis Y, Jarmale S, Melanson R, Bonanno K, Schoolcraft K, Miller PG, Condurat AL, Gonzalez EM, Qian K, Morin E, Langhnoja J, Lupien LE, Rendo V, Digiacomo J, Wang D, Zhou K, Kumbhani R, Guerra Garcia ME, Sinai CE, Becker S, Schneider R, Vogelzang J, Krug K, Goodale A, Abid T, Kalani Z, Piccioni F, Beroukhim R, Persky NS, Root DE, Carcaboso AM, Ebert BL, Fuller C, Babur O, Kieran MW, Jones C, Keshishian H, Ligon KL, Carr SA, Phoenix TN and Bandopadhayay P.

    PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation

    NATURE COMMUNICATIONS . 13(1): 604-604. Nº de cites: 21

    [doi:10.1038/s41467-022-28198-8]

  • Pascual-Pastó G, Castillo H, Unceta N, Aschero MR, Resa-Parés C, Gómez-Caballero A, Vilà-Ubach M, Muñoz-Aznar O, Suñol M, Burgeño-Sandoval V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J and Carcaboso AM.

    SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas

    JOURNAL OF CONTROLLED RELEASE . 342: 81-92. Nº de cites: 12

    [doi:10.1016/j.jconrel.2021.12.035]

  • Carvalho DM, Richardson PJ, Olaciregui N, Stankunaite R, Lavarino C, Molinari V, Corley EA, Smith DP, Ruddle R, Donovan A, Pal A, Raynaud FI, Temelso S, Mackay A, Overington JP, Phelan A, Sheppard D, Mackinnon A, Zebian B, Al-Sarraj S, Merve A, Pryce J, Grill J, Hubank M, Cruz-Martínez O, Morales-La Madrid A, Mueller S, Carcaboso AM, Carceller F and Jones C.

    Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

    CANCER DISCOVERY . 12(2): 416-431. Nº de cites: 23

    [doi:10.1158/2159-8290.CD-20-1201]